A stealth-mode startup backed by one of Boston’s biggest venture capital firms, Flagship Pioneering, is planning to graduate from shared lab space to a much larger leased lab in Kendall Square, and is expecting to more than triple its staff by 2020, according to new details made public for the first time Thursday.
The company — still referred to by its stealth-mode moniker “VL49” — is one of several new startups trying to leverage three buzzy technologies: artificial intelligence, CRISPR, and single-celled sequencing.
“Stealth mode” means its staff won’t discuss its existence with the media and its leaders have not publicly announced what they’re doing. Companies might choose to stay in stealth mode for a few reasons: For example, some executives might choose not to discuss their company’s work until they’re pretty sure they understand all the potential pitfalls their approach might have.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
